Aim: The aim of the study is to assess tumor response, treatment-related toxicities, progression-free survival (PFS), and overall survival (OS) in patients with relapsed/refractory brain tumors treated with bevacizumab-containing regimen. Methods: Patients that had received I and II line treatments with or without megatherapy were included. Doses and schedule were as follows: bevacizumab (BVZ) 10 mg/kg i.v. with irinotecan (IRI) 150 mg/m 2 i.v. every 2 weeks ± temozolamide (TMZ) 200 mg/m 2 p.o. daily for 5 days every 4 weeks. TMZ was omitted in heavily pretreated cases. Results: Between 2013 and 2018, 12 patients (3F/9M), median age 161 months (range 66–348), affected with medulloblastoma (n 7), or low-grade glioma (n 2), or high-grade glioma (n 3), received BVZ/IRI association (median courses 20, range 4–67); 3 of them continued single-agent BVZ (median courses 23, range 8–39). TMZ (median courses 8, range 2–26) was administered in eight patients and then stopped in three of them because of myelotoxicity or lack of compliance. Treatment was well tolerated. After 3 months, two complete responses, two partial responses, seven stable diseases, and one progressive disease were observed. Nine cases experienced an improvement in neurological symptoms. Median time to progression was 11 months (95% confidence interval, 4–18 months). Six-month and 2-year PFS were 75% and 42%, respectively. The OS is 33%; interestingly, two cases (one medulloblastoma and one high-grade glioma) are progression-free off-therapy since 30 and 48 months, respectively. Conclusions: BVZ/IRI association ± TMZ showed encouraging therapeutic activity and low toxicity in this series of relapsed/refractory brain tumors.

Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience / Schiavetti, A.; Varrasso, G.; Mollace, M. G.; Dominici, C.; Ferrara, E.; Papoff, P.; Di Biasi, C.. - In: CHILDS NERVOUS SYSTEM. - ISSN 0256-7040. - 35:6(2019), pp. 1007-1012. [10.1007/s00381-019-04117-z]

Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience

Schiavetti A.;Varrasso G.;Mollace M. G.;Dominici C.;Ferrara E.;Papoff P.;Di Biasi C.
2019

Abstract

Aim: The aim of the study is to assess tumor response, treatment-related toxicities, progression-free survival (PFS), and overall survival (OS) in patients with relapsed/refractory brain tumors treated with bevacizumab-containing regimen. Methods: Patients that had received I and II line treatments with or without megatherapy were included. Doses and schedule were as follows: bevacizumab (BVZ) 10 mg/kg i.v. with irinotecan (IRI) 150 mg/m 2 i.v. every 2 weeks ± temozolamide (TMZ) 200 mg/m 2 p.o. daily for 5 days every 4 weeks. TMZ was omitted in heavily pretreated cases. Results: Between 2013 and 2018, 12 patients (3F/9M), median age 161 months (range 66–348), affected with medulloblastoma (n 7), or low-grade glioma (n 2), or high-grade glioma (n 3), received BVZ/IRI association (median courses 20, range 4–67); 3 of them continued single-agent BVZ (median courses 23, range 8–39). TMZ (median courses 8, range 2–26) was administered in eight patients and then stopped in three of them because of myelotoxicity or lack of compliance. Treatment was well tolerated. After 3 months, two complete responses, two partial responses, seven stable diseases, and one progressive disease were observed. Nine cases experienced an improvement in neurological symptoms. Median time to progression was 11 months (95% confidence interval, 4–18 months). Six-month and 2-year PFS were 75% and 42%, respectively. The OS is 33%; interestingly, two cases (one medulloblastoma and one high-grade glioma) are progression-free off-therapy since 30 and 48 months, respectively. Conclusions: BVZ/IRI association ± TMZ showed encouraging therapeutic activity and low toxicity in this series of relapsed/refractory brain tumors.
File allegati a questo prodotto
File Dimensione Formato  
Schiavetti_Bevacizumab-containing_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1304287
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact